Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 55,694 shares at $39.27 ($2.2M) on 2021-02-19, disclosed to the SEC on 2021-02-22.
Open-market sale of $2.2M ITCI by Chairman, President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.91 | 3,100 | $121K | 5.5% |
| 2 | $38.91 | 3,100 | $121K | 5.5% |
| 3 | $39.27 | 24,747 | $972K | 44.5% |
| 4 | $39.27 | 24,747 | $972K | 44.5% |
| Total | $39.23 avg | 55,694 | $2.2M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |